Form 4: Tango Therapeutics Director Equity Grant
Director Equity Compensation Disclosure
Director Lesley Ann Calhoun received an equity grant of 4,000 restricted stock units and 25,000 stock options from Tango Therapeutics.
Summary
- Director Lesley Ann Calhoun was granted 4,000 restricted stock units (RSUs) on June 5, 2026.
- The RSUs vest on the earlier of June 5, 2027, or the date of the next annual stockholders meeting.
- A stock option grant for 25,000 shares was issued with an exercise price of $20.22.
- The stock options vest in 12 equal monthly installments starting July 5, 2026.
- Following these transactions, the director holds 16,500 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standard vesting schedules encourage director retention.
Negatives
- Equity grants result in minor dilution to existing shareholders.
Risks
- Vesting is contingent upon the director's continuous service to the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure alignment between leadership and long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of both RSUs and stock options is consistent with compensation structures at mid-cap biotech firms.
- Vesting periods of one year for director equity are standard practice for maintaining board stability.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Lesley Ann Calhoun appointed Julie Fogarty and Matthew Gall as attorneys-in-fact for SEC filings. | 06/07/2026 | Standard administrative procedure to ensure timely regulatory compliance. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of stock options beginning July 5, 2026.
- Vesting of RSUs on June 5, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 06/05/2026 | Date of equity grant and earliest transaction. |
| 06/07/2026 | Execution date of Power of Attorney. |
| 06/08/2026 | Filing date of the Form 4. |
| 07/05/2026 | First vesting date for stock options. |
| 06/05/2027 | Vesting date for restricted stock units. |
| 06/05/2036 | Expiration date of stock options. |
Keywords
Tango Therapeutics, TNGX, Form 4, Director Compensation, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.